2-pyridineboronic acid N-phenyldiethanolamine ester | 882521-96-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-pyridineboronic acid N-phenyldiethanolamine ester
• 英文别名: 6-phenyl-2-pyridin-2-yl-1,3,6,2-dioxazaborocane
• CAS: 882521-96-2
• 化学式: C₁₅H₁₇BN₂O₂
• 分子量: 268.123
• InChiKey: QDIQDVHNUYDVDD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.33
• 重原子数：
  20
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  34.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-pyridineboronic acid N-phenyldiethanolamine ester 在 bis-triphenylphosphine-palladium(II) chloride 、 potassium phosphate 、 copper(l) iodide 、 四(三苯基膦)钯 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 7.83h， 生成 PyPm2DBF-01
  参考文献：
  名称：

  유기 화합물, 발광 소자, 디스플레이 모듈, 조명 모듈, 발광 장치, 표시 장치, 전자 기기, 및 조명 장치

  摘要：

  本发明提供了一种新的有机化合物。或者，提供了可用作发光器件的电子传输材料的有机化合物。该有机化合物包含在二苯并噻吩的2位和8位分别结合有两个吡啶环的复杂芳香烃。该有机化合物可用作发光器件的电子传输材料。

  公开号：

  KR20150055553A
• 作为产物：
  描述：

  2-溴吡啶 、 硼酸三异丙酯 、 N,N-二羟乙基苯胺 在 正丁基锂 、 异丙醇 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 20.0h， 以75%的产率得到2-pyridineboronic acid N-phenyldiethanolamine ester
  参考文献：
  名称：

  The preparation of a stable 2-pyridylboronate and its reactivity in the Suzuki–Miyaura cross-coupling reaction

  摘要：

  The preparation and reactivity of a 2-pyridylboronate stabilised by N-phenyldiethanolamine is described. In Suzuki-Miyaura cross-coupling reactions employing this boronate, significant aryl-aryl exchange from the phosphine ligand was observed with some combinations of ligand and substrates. The amount of the exchange by-product can be minimised by appropriate choice of phosphine ligand. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2003.11.068

文献信息

• [EN] NOVEL HETEROCYCLIC COMPOUNDS AS ANTIMALARIAL AGENTS<br/>[FR] NOUVEAUX COMPOSÉS HÉTÉROCYCLIQUES UTILES EN TANT QU'AGENTS ANTIPALUDIQUES
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2015028989A1

  公开（公告）日：2015-03-05

  The invention relates to novel heterocyclic compounds of the Formula I. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more compounds of the Formula I and especially their use as medicaments to treat or prevent malaria infections or to treat or prevent other protozoal diseases like sleeping sickness, Chagas disease, amebiasis, giardiasis, trichomoniasis, toxoplasmosis, and leishmaniasis.

  本发明涉及式I的新颖杂环化合物。本发明还涉及包括制备化合物的方法、包含式I的一个或多个化合物的药物组合物，尤其是它们作为药物用于治疗或预防疟疾感染或治疗或预防其他原虫疾病，如昏睡病、查加斯病、阿米巴病、贾第虫病、滴虫病、弓形虫病和利什曼病。
• Synthesis of 2,2′-Bipyridines via Suzuki-Miyaura Cross-Coupling
  作者：Arne Lützen、Christoph Gütz

  DOI：10.1055/s-0029-1217082

  日期：2010.1

  For a long time, the Suzuki-Miyaura cross-coupling reaction could not be used for the synthesis of 2,2′-bipyridines due to the lack of sufficiently stable 2-pyridylboron compounds. Stabilized 2-pyridylboronic acid esters recently developed by Hodgson, however, were found to be ideally suited for this purpose. Two general protocols could be developed and demonstrated to be valuable alternatives, which

  长期以来，由于缺乏足够稳定的2-吡啶基硼化合物，Suzuki-Miyaura交叉偶联反应无法用于2,2'-联吡啶的合成。然而，发现霍奇森最近开发的稳定的2-吡啶基硼酸酯是理想地适合于此目的的。可以开发出两种通用方案，并证明它们是有价值的替代方案，可以非常有效地用于官能化2，2'-联吡啶的合成。 交叉偶联反应-联吡啶-钯-2-吡啶基硼酸酯-铃木宫浦反应
• Spiro Compounds As NPY Y5 Receptor Antagonists
  申请人：Biagetti Matteo

  公开号：US20090203705A1

  公开（公告）日：2009-08-13

  The present invention relates to novel compounds of formula (I), or a pharmaceutically acceptable salt thereof, wherein R is an aryl or heteroaryl, which may be substituted by one or more: halogen, C 1 -C 4 alkyl, C1-C4 alkoxy, C 1 -C 4 haloalkyl, C 1 -C 4 haloalkoxy, cyano; Z 1 is H, C 1 -C 4 alkyl or F; Z is CH 2 , CH(C 1 -C 4 alkyl), C(C 1 -C 4 alkyl) 2 or a bond; A is a 6-10 membered aryl or heteroaryl, which may be substituted by one or more: halogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkyl, C 1 -C 4 haloalkoxy, cyano; or —C(═O)—X; or —O(CH 2 ) 0-1 R 1 ; B is hydrogen or is a 5-6 membered heteroaryl, or a 4-6 membered heterocycle, or phenyl, which may be substituted by one or more: halogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkyl, C 1 -C 4 haloalkoxy, hydroxyl, cyano; A and B being linked via any atom; R 1 is —(C 1 -C 4 )alkyl(C 1 -C 4 )alkoxy; or C 3 -C 8 cycloalkyl; or R 1 is an aryl or heteroaryl, which may be substituted by one or more: halogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkyl, C 1 -C 4 haloalkoxy, cyano; or R 1 is a 4-6 membered heterocycle, which may be substituted by one or more: halogen, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 haloalkyl, C 1 -C 4 haloalkoxy, cyano; X is OR 2 or NR 3 R 4 ; R 2 is C 1 -C 4 alkyl; R 3 is hydrogen or together with R 4 and the nitrogen form a 5-6 saturated membered ring; R 4 is C 3 -C 8 cycloalkyl; processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as NPY Y5 receptor antagonists and as agents for the treatment and/or prophylaxis of eating disorders such as a binge eating disorder.

  本发明涉及式(I)的新化合物或其药学上可接受的盐，其中R是芳基或杂芳基，可以被一个或多个卤素、C1-C4烷基、C1-C4氧烷基、C1-C4卤代烷基、C1-C4卤代氧烷基、氰基取代；Z1是H、C1-C4烷基或F；Z是CH2、CH(C1-C4烷基)、C(C1-C4烷基)2或键；A是一个6-10成员芳基或杂芳基，可以被一个或多个卤素、C1-C4烷基、C1-C4氧烷基、C1-C4卤代烷基、C1-C4卤代氧烷基、氰基或—C(═O)—X取代；或—O(CH2)0-1R1；B是氢或是一个5-6成员杂芳基、或一个4-6成员杂环、或苯基，可以被一个或多个卤素、C1-C4烷基、C1-C4氧烷基、C1-C4卤代烷基、C1-C4卤代氧烷基、羟基、氰基取代；A和B通过任何原子连接；R1是—(C1-C4)烷基(C1-C4)氧基；或C3-C8环烷基；或R1是一个芳基或杂芳基，可以被一个或多个卤素、C1-C4烷基、C1-C4氧烷基、C1-C4卤代烷基、C1-C4卤代氧烷基、氰基取代；或R1是一个4-6成员杂环，可以被一个或多个卤素、C1-C4烷基、C1-C4氧烷基、C1-C4卤代烷基、C1-C4卤代氧烷基、氰基取代；X是OR2或NR3R4；R2是C1-C4烷基；R3是氢或与R4和氮一起形成一个5-6饱和成员环；R4是C3-C8环烷基；它们的制备方法，用于这些方法的中间体，含有它们的药物组合物以及它们作为NPY Y5受体拮抗剂和用于治疗和/或预防暴饮暴食等进食障碍的药物的用途。
• [EN] BENZOTHIAZOLES AS GHRELIN RECEPTOR MODULATORS<br/>[FR] AGENTS THÉRAPEUTIQUES - 802
  申请人：ASTRAZENECA AB

  公开号：WO2009047558A1

  公开（公告）日：2009-04-16

  A compound of formula (I) or a pharmaceutically acceptable salt thereof in which R1, R2 , R3, R4 and m are as described in the specification for use in the treatment of obesity and/or diabetes.

  化合物的分子式（I）或其药用盐，其中R1、R2、R3、R4和m如说明书中所述，用于治疗肥胖和/或糖尿病。
• [EN] AMPK INHIBITORS<br/>[FR] INHIBITEURS D'AMPK
  申请人：UNIV SYDDANSK

  公开号：WO2019106087A1

  公开（公告）日：2019-06-06

  The 5'-AMP-activated protein kinase AMPK functions as a master switch to maintain cellular and whole-body energy homeostasis and abnormal activity profiles of AMPK may cause pathological disorders. The present invention relates to a series of compounds (I) based on a pyrrolo[2,3-c]pyridine and a thieno[2,3- c]pyridine scaffold as AMPK inhibitors. In particular, the present invention relates to the synthesis of such compounds and the medical use of such compounds.

  5'-AMP激活的蛋白激酶AMPK作为细胞和整体能量稳态的主要开关，AMPK的异常活性可能导致病理性疾病。本发明涉及一系列基于吡咯并[2,3-c]吡啶和噻吩[2,3-c]吡啶骨架的化合物(I)作为AMPK抑制剂。具体而言，本发明涉及这类化合物的合成以及这类化合物的医药用途。